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The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) has
launched several large-scale trials to determine the best strategies for gaining and sustain-
ing control of schistosomiasis and transitioning toward elimination. In Côte d’Ivoire, a 5-year
cluster-randomized trial is being implemented in 75 schools to sustain the control of schisto-
somiasis mansoni. We report Schistosoma mansoni infection levels in children one year
after the initial school-based treatment (SBT) with praziquantel and compare with baseline
results to determine the effect of the intervention.
Methodology
The baseline cross-sectional survey was conducted in late 2011/early 2012 and the first fol-
low-up in May 2013. Three consecutive stool samples were collected from 9- to 12-year-old
children in 75 schools at baseline and 50 schools at follow-up. Stool samples were sub-
jected to duplicate Kato-Katz thick smears. Directly observed treatment (DOT) coverage of
the SBT was assessed and the prevalence and intensity of S.mansoni infection compared
between baseline and follow-up.
Principal Findings
The S.mansoni prevalence in the 75 schools surveyed at baseline was 22.1% (95% confi-
dence interval (CI): 19.5–24.4%). The DOT coverage was 84.2%. In the 50 schools sur-
veyed at baseline and one year after treatment, the overall prevalence of S.mansoni
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infection decreased significantly from 19.7% (95% CI: 18.5–20.8%) to 12.8% (95% CI:
11.9–13.8%), while the arithmetic mean S.mansoni eggs per gram of stool (EPG) among
infected children slightly increased from 92.2 EPG (95% CI: 79.2–105.3 EPG) to 109.3 EPG
(95% CI: 82.7–135.9 EPG). In two of the 50 schools, the prevalence increased significantly,
despite a DOT coverage of >75%.
Conclusions/Significance
One year after the initial SBT, the S.mansoni prevalence had decreased. Despite this posi-
tive trend, an increase was observed in some schools. Moreover, the infection intensity
among S.mansoni-infected children was slightly higher at the 1-year follow-up compared to
the baseline situation. Our results emphasize the heterogeneity of transmission dynamics
and provide a benchmark for the future yearly follow-up surveys of this multi-year SCORE
intervention study.
Author Summary
Schistosomiasis is a parasitic worm disease that is widespread in sub-Saharan Africa. To
better understand how to gain and sustain the control of schistosomiasis and how to elimi-
nate this disease in different epidemiologic settings, the Schistosomiasis Consortium for
Operational Research and Evaluation (SCORE) has launched several multi-year studies
that are being implemented in East and West Africa. This article highlights how the Schis-
tosoma mansoni infection levels changed one year after an initial treatment with the anti-
worm drug praziquantel given to children aged 5–15 years in western Côte d’Ivoire. Infec-
tion and treatment data at school level were available from more than 4,600 children in 50
schools. One year after the treatment that had been received by more than 80% of the chil-
dren, the overall S.mansoni prevalence decreased from 19.7% to 12.8%, while the intensity
of infection among S.mansoni-positive children slightly increased. In several schools, the
S.mansoni intensity and, particularly the prevalence, increased unexpectedly. Our findings
show that the dynamics of schistosomiasis transmission varies from one village to another.
It will be interesting to monitor changes over longer time periods as this SCORE study
unfolds.
Introduction
Schistosomiasis is a neglected tropical disease that exerts a considerable public health problem
in 78 tropical and subtropical countries [1]. In 2013, it was estimated that schistosomiasis
affected more than 250 million people worldwide with 90% of the reported cases concentrated
in sub-Saharan Africa [2]. Since the mid-1980s, the World Health Organization (WHO)
emphasizes morbidity control using the drug praziquantel as the main pillar of the global strat-
egy to fight schistosomiasis [3]. Praziquantel is the drug of choice because it is efficacious
against the adult stages of all Schistosoma species parasitizing humans, is inexpensive (the aver-
age cost to treat a school-aged child was US$ 0.2 per treatment in 2013), and has a good safety
profile [4–8]. For morbidity control, praziquantel is being administered to at-risk populations
without prior diagnosis, a strategy commonly known as ‘preventive chemotherapy’ [9].
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The recommended frequency of drug administration is based on the level of endemicity in a
given study area. According to WHO, in areas with high schistosomiasis endemicity (preva-
lence50%), all school-aged children and adult people at risk of infection should be treated
annually [10]. In areas with moderate endemicity (prevalence 10–50%), all school-aged chil-
dren should be treated once every two years. In low endemic areas (prevalence<10%), school-
aged children should be treated twice during their time in school; first at school entry and then
again in their last year of schooling [11,12]. However, these prevalence thresholds are arbitrary.
Hence, the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE)
launched a series of studies to strengthen the evidence-base how best to gain and sustain the
control of schistosomiasis, including cost considerations [13]. Two 5-year cluster-randomized
trials are being implemented in Côte d’Ivoire and Kenya [14,15]. These trials are school-based
with three treatment arms (25 schools per arm) and aim to assess whether annual school-based
treatment (SBT) with praziquantel for four years (arm A), annual SBT in years 1 and 2, fol-
lowed by “drug holidays” in years 3 and 4 (arm B), or SBT in years 1 and 3, spaced by“drug hol-
idays” in years 2 and 4 (arm C) will substantially reduce the prevalence and intensity of
Schistosoma infection and keep infection at low levels.
Here, we present the effect of the first SBT with praziquantel on Schistosoma mansoni infec-
tion among school-aged children in western Côte d’Ivoire, as revealed by a detailed follow-up
survey conducted in May 2013, compared to baseline data collected from December 2011 to
February 2012. Specifically, we determined changes in the prevalence and intensity of S.man-
soni infections among children in the 50 schools that belong to treatment arms A and B, and
discuss consequences for the ongoing cluster-randomized trial and, more generally, for schisto-
somiasis control interventions in Côte d’Ivoire and elsewhere.
Methods
Ethics Statement
The study protocol was approved by the institutional research commissions of the Swiss Tropi-
cal and Public Health Institute (Basel, Switzerland) and the ‘Centre Suisse de Recherches Scien-
tifiques en Côte d’Ivoire’ (CSRS; Abidjan, Côte d’Ivoire). Ethical approval was obtained from
the ethics committees in Basel (reference no. EKBB 279/10) and the Ministry of Public Health
in Côte d’Ivoire (reference no. 1994 MSHP/CNER).
At the onset of the study, regional directors of the education and health sectors, education
inspectors, village authorities, local community members, and teachers were sensitized in detail
about the objectives of the research project. Parents and guardians of study participants pro-
vided written informed consent for children to participate. After the baseline parasitologic sur-
vey, in the frame of the first SBT conducted in June 2012, school-aged children living in the
catchment area of participating schools were offered treatment with praziquantel at a single
oral dose of 40 mg/kg of body weight [16].
Study Area and Population
The baseline survey was carried out from December 2011 to February 2012, the SBT in June
2012, and the first follow-up survey was conducted in May 2013 in eligible schools located in
four regions of western Côte d’Ivoire: Cavally, Guemon, Haut-Sassandra, and Tonkpi. Details
of the study area and population surveyed have been described elsewhere [15,17]. The Cavally
and Sassandra rivers and their tributaries represent the major hydrographic features of the
study area [18,19]. Buyo, a hydroelectric dam built across the Sassandra River in 1981, formed
a lake with an estimated surface area of 600 km² [20]. In western Côte d’Ivoire, the sources of
water are traditional wells, rain water, rivers, water supply dams, ponds, creeks, fountains,
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natural spring water, and tap water [21]. The main reasons for human water contact that might
lead to schistosomiasis transmission are washing dishes, washing children, fetching water, fish-
ing, swimming, farming, and playing [22]. Despite the existence of latrines in numerous house-
holds, open defecation is commonly practiced [22–24].
Sample Size
The aim of the SCORE sustaining schistosomiasis control study implemented in western Côte
d’Ivoire is to determine the best strategy of preventive chemotherapy with praziquantel to sus-
tain schistosomiasis mansoni control in moderate endemicity settings [15,17]. For this pur-
pose, the S.mansoni prevalence in n schools in three treatments arms is compared over a study
period of four years. The prevalence of S.mansoni is determined by testingm children in those
schools where there is subsequent treatment. The effect of the different treatment intervals on
the S.mansoni prevalence will be estimated using the following logistic regression model: log
(pijt / (1 − pijt)) = μ +αi + βt + ɣik, where pijt denotes the prevalence of S.mansoni in school j
receiving treatment i in year t, μ is an intercept term, αi is the effect of treatment i, βt is the
effect of time t, and γik is the time by treatment interaction. Generalized estimating equations
have been used to fit these longitudinal data [25]. To take into account variation in the S.man-
soni prevalence among schools, an overdispersion parameter φ was introduced into the model.
When φ = 1, all schools under the same treatment have identical prevalences, whereas φ
increases with increasing variation of prevalence levels between villages.
The calculations revealed that studying 20 schools per arm and evaluating 100 individuals
per school would result in minimum effect sizes of 5–12% with or without overdispersion. In
order to increase the chance of detecting differences between the intervention arms, the num-
ber of intervention units was increased to 25 per arm. Consequently, a total of 75 schools with
a S.mansoni prevalence of 10–24% according to results from an eligibility survey were ran-
domized to one of the three treatment arms [15]. Treatment arm A receives SBT with prazi-
quantel once every year for four years, arm B receives SBT in years 1 and 2, followed by “drug
holidays” in years 3 and 4, and arm C receives SBT in years 1 and 3, alternated by “drug holi-
days” in years 2 and 4 [15]. Before administration of the first round of treatment, a detailed
baseline survey was conducted.
Study Procedures
Following the SCORE harmonization protocol, all 75 schools were included in the baseline par-
asitologic survey implemented in Côte d’Ivoire from December 2011 to February 2012. Chil-
dren were treated with praziquantel in June 2012. Only the 50 schools belonging to treatment
arms A and B were subjected to the first follow-up survey carried out in May 2013, while the 25
schools belonging to treatment arm C were not subjected to a follow-up survey, as they were
on “drug holidays” in year 2.
Baseline and follow-up surveys pursued cross-sectional designs. Study procedures have
been detailed elsewhere [15,17]. In brief, in each of the selected schools, approximately 100
children were invited to participate in the study. Inclusion criteria were as follows: (i) age of
children ranging between 9 and 12 years; (ii) presence of an informed consent sheet signed by
parents/guardians; and (iii) children themselves assented orally. Over three consecutive days,
children were invited to submit a portion of their own morning stool in a 125-ml plastic con-
tainer. Every day, filled stool containers were collected by trained field enumerators and sent to
the hospital laboratories in the towns of Biankouma, Danané, Douékoué, Guiglo, Kouibly, and
Man for processing.
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Stool specimens were subjected to the Kato-Katz method [26]. In brief, duplicate Kato-Katz
thick smears were prepared from a single stool sample, using 41.7 mg plastic templates. The
thick smears were allowed to clear for at least 60 min and examined by experienced laboratory
technicians under a light microscope at low magnification. Eggs from S.mansoni, and addi-
tionally from soil-transmitted helminth species, were counted and recorded for each species
separately. For quality control, 10% of the slides were randomly selected and re-read by a senior
microscopist. In case of discrepancies, the results were discussed with the concerned microsco-
pists and the slides re-read until agreement was reached [27].
Praziquantel Administration
In June 2012, children aged 5–15 years enrolled in the 75 study schools and non-enrolled
school-aged children living in the school catchment areas were offered free-of-charge treat-
ment with praziquantel (40 mg/kg) using a dose pole according to WHO guidelines [16]. Prazi-
quantel was administered by trained teachers to children, following a directly observed
treatment (DOT) approach. Children remained under medical observation and adverse events
were recorded within 4 hours post-treatment. Treatment was led by the ‘Programme National
de Lutte contre la Schistosomiase, les Géohelminthiases et la Filariose Lymphatique’
(PNL-SGF), and supported by staff from the ‘Programme National de Santé Scolaire et Univer-
sitaire’ (PNSSU), the CSRS, and the ‘Université Félix Houphouët-Boigny’. Praziquantel tablets
were supplied by the Schistosomiasis Control Initiative (SCI; London, United Kingdom).
The overall number of school-aged children residing in each village was obtained by adding
up the number of school-aged but non-school attending children as recorded by the commu-
nity health workers and the number of children registered in school, as detailed by school
teachers. Trained teachers administered praziquantel to children (those attending school, and
the non-enrolled children) and recorded the number of treated children.
Statistical Analysis
Baseline survey data were entered into Microsoft Excel (2010 Microsoft Corporation), while
data from the first follow-up survey were directly entered into smartphones and then uploaded
to a database maintained on a central server (Open Data Kit) in Atlanta, United States of
America. Statistical analyses were performed with STATA version IC13.1 (Stata Corporation;
College Station, United States of America). The final analysis included children aged 9–12
years who had at least four Kato-Katz thick smear readings at the parasitologic surveys done
both at baseline and follow-up. To obtain individuals’ eggs per gram of feces (EPG), we divided
the total S.mansoni egg counts from the multiple Kato-Katz slides per child by the total num-
ber of Kato-Katz thick smears and multiplied by a factor of 24. S.mansoni-positive individuals
were stratified into three infection intensity categories: (i) light (1–99 EPG), (ii) moderate
(100–399 EPG), and (iii) heavy (400 EPG) [16]. Moreover, we calculated S.mansoni preva-
lence and arithmetic mean (AM) EPG for positive individuals per school and treatment arm.
With regard to soil-transmitted helminth infections that were also identified with the Kato-
Katz technique, a child was considered positive if at least one egg of Ascaris lumbricoides, hook-
worm, or Trichuris trichiura was detected in one of the slides.
We employed a χ² test to assess a potential association between S.mansoni prevalence and
age or sex. Reduction in the prevalence and intensity of S.mansoni infection per school was cal-
culated using the following formulae [28]: prevalence reduction = [(prevalence at baseline—
prevalence at first follow-up) / (prevalence at baseline)] X 100. Reduction in the intensity of
infection = [(AM EPG at baseline—AM EPG at first follow-up) / (AM EPG at baseline)] X 100.
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The treatment coverage rate was assessed by using the following formula: coverage of the
mass drug administration (MDA) = [(number of school-aged children with DOT recorded by
teachers) / (overall number of school-aged children registered in school and recorded by health
workers)] X 100.
Geographic coordinates of each school were recorded using a hand-held global positioning
system (GPS) receiver (Garmin Etrex 30; Olathe, United States of America). Arc Map 10.2.1
(Environmental Systems Research Institute Inc.; Redlands, United States of America) was used
to generate maps of the changes of S.mansoni prevalence and intensity of infection (AM EPG)
from baseline to follow-up.
Results
Operational Results from the Baseline Survey
The baseline survey was conducted in the 75 schools meeting eligibility criteria from December
2011 to February 2012, and 7,478 children were invited to participate (Fig 1). Among them,
168 pupils were excluded from further analyses, because their age was outside the 9–12 years
range. Additionally, 299 children were excluded because they did not provide sufficient stool to
prepare at least quadruplicate Kato-Katz thick smears. The final study population for analysis
of the baseline survey consisted of 7,011 children. There were more boys (n = 4,173) than girls
(n = 2,838). The mean age was 10.5 years. The number of children in treatment arms A, B, and
C was 2,410 (34.4%), 2,348 (33.5%), and 2,253 (32.1%), respectively.
Fig 1. Study participation of schoolchildren at the baseline survey and one-year follow-up survey. The flowcharts show the study participation of 9- to
12-year-old schoolchildren at the baseline survey (A), which was conducted from December 2011 to February 2012, and the first follow-up survey (B), which
was carried out one-year post-treatment in May 2013, in western Côte d’Ivoire.
doi:10.1371/journal.pntd.0004329.g001
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Operational Results from Follow-Up Survey
In May 2013, 4,966 children from the 50 schools belonging to intervention arms A and B were
invited to participate in the first follow-up survey. According to the SCORE harmonization
protocol, children attending schools belonging to study arm C were not surveyed. Among the
pupils attending schools included in arms A and B, who were invited to participate, 49 children
had an age outside the 9–12 years range, and 250 children did not provide enough stool for at
least quadruplicate Kato-Katz thick smears. Hence, results of 4,667 children were included for
further statistical analyses. There were more boys (n = 2,640) than girls (n = 2,027). The chil-
dren’s mean age was 10.3 years. There were 2,379 children in treatment arm A and 2,288 in
treatment arm B.
S.mansoni Infection at Baseline
At baseline, before the implementation of the first SBT with praziquantel, the examination of
at least four Kato-Katz thick smears per child revealed an overall S.mansoni prevalence of
22.1% among the 75 schools surveyed. The prevalence at the unit of the school ranged from
1.0% to 54.0%. S.mansoni infection was significantly associated with age (χ² = 25.2, p<0.001),
higher prevalence was predominantly observed among older children. The prevalence of S.
mansoni was significantly higher among boys than girls (24.3% versus 18.7%; χ² = 29.9, p
<0.001). The overall S.mansoni prevalence in treatment arms A, B, and C was 18.8% (95% CI:
17.2–20.3%), 20.5% (95% CI: 18.9–22.2%), and 27.2% (95% CI: 25.3–29.0%), respectively.
With regard to the AM infection intensity, the respective values were 93.5 EPG (95% CI: 62.6–
124.4 EPG), 96.2 EPG (95% CI: 74.5–117.9 EPG), and 88.1 EPG (95% CI: 71.5–104.7 EPG)
(Table 1).
Changes of S.mansoni Prevalence at Follow-Up Survey
As summarized in Table 1, at the first follow-up survey, the overall S.mansoni prevalence in
arms A and B showed a statistically significant decline from 19.7% (95% CI: 18.5–20.8%) at
baseline to 12.8% (95% CI: 11.9–13.8%) at the 1-year follow-up. In arm A, a decrease from
18.8% (95% CI: 17.2–20.3%) to 11.2% (95% CI: 9.9–12.4%) was observed, corresponding to a
reduction of 40.4%, while in arm B the prevalence declined from 20.5% (95% CI: 18.9–22.2%)
to 14.5% (95% CI: 13.1–16.0%), a reduction of 29.3%.
Fig 2 indicates the dynamics of the S.mansoni prevalence from baseline to first follow-up
survey on a school-by-school basis, stratified by treatment arm. Among the 25 schools belong-
ing to treatment arm A, the S.mansoni prevalence dropped in 23 schools (S1 Table). The most
significant decreases occurred in Dio, Pona 2, Siambly, and Gregbeu, where at the 1-year fol-
low-up, no eggs of S.mansoni were found in the stool of the children examined. However, in
Biélé, the S.mansoni prevalence increased significantly from 36.0% (95% CI: 26.4–45.6%) to
79.0% (95% CI: 70.9–87.1%), while a non-significant increase from 12.0% (95% CI: 5.5–18.5%)
to 20.7% (95% CI: 12.0–29.4%) was observed in Séohoun-Guiglo.
In treatment arm B, the prevalence of S.mansoni decreased in 20 out of the 25 schools
included (S1 Table). In two schools, the prevalence dropped prominently to zero from 24.0%
in Semien and from 25.6% in Diehiba. A significant increase in the S.mansoni prevalence was
observed in Ziondrou from 31.6% (95% CI: 22.0–41.1%) to 62.0% (95% CI: 52.3–71.7%). An
increase in prevalence was also observed in Dah, Douandrou 1, Koulouan, and Guessabo 2, but
without statistical significance.
Taken together, as shown in Fig 3A, among the 50 schools surveyed at the first follow-up, a
reduction of the S.mansoni prevalence of 25% and above was observed in 39 schools (78.0%).
In six schools, the changes ranged from -25% to +25%. An increase of 25% and above was
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recorded in five schools (10.0%). The increase in prevalence was observed mainly in the central
part of Guemon region, eastern Tonkpi region, and western part of Haut-Sassandra region.
Changes of S.mansoni Infection Intensity at Follow-Up Survey
The overall S.mansoni AM EPG in arms A and B increased from 94.9 EPG (95% CI: 76.2–
113.6 EPG) at baseline to 109.3 EPG (95% CI: 82.7–135.9 EPG) at the 1-year follow-up survey.
However, this increase was not statistically significant. As shown in Table 2, in arm A, an
increase from 93.5 EPG (95% CI: 62.6–124.4 EPG) to 123.7 EPG (95% CI: 70.7–176.7 EPG)
was observed, corresponding to an increase of 32.3%, while in arm B the AM EPG at baseline
(96.2 EPG, 95% CI: 74.5–117.9 EPG) and the 1-year follow-up (97.8 EPG, 95% CI: 75.5–120.0
EPG) remained basically the same. The proportion of children with heavy infections (400
EPG) increased from 4.9% to 6.3%.
Fig 4 displays the changes of the S.mansoni AM EPG in all the schools of treatment arms A
and B from baseline to the first follow-up. In arm A, the S.mansoni AM EPG decreased in 16
Table 1. S.mansoni and soil-transmitted helminth infection prevalence at the baseline and follow-up surveys, stratified by treatment arm.
Arms Baseline One-year post-treatment Change
Examined Infected Prevalence Examined Infected Prevalence
N N (%) (95% CI) N N (%) (95% CI) (%)
Arm A
S. mansoni 2,410 453 18.8 (17.2–20.3) 2,379 266 11.2 (9.9–12.4) -40.4
Hookworm 2,410 16 0.7 (0.3–1.0) 2,379 2 0.1 (0.0–0.2) -85.7
A. lumbricoides 2,410 23 0.9 (0.6–1.3) 2,379 11 0.5 (0.2–0.7) -44.4
T. trichiura 2,410 82 3.4 (2.7–4.1) 2,379 42 1.8 (1.2–2.3) -47.1
Arm B
S. mansoni 2,348 482 20.5 (18.9–22.2) 2,288 332 14.5 (13.1–16.0) -29.3
Hookworm 2,348 24 1.0 (0.6–1.4) 2,288 2 0.1 (0.0–0.2) -90.0
A. lumbricoides 2,348 12 0.5 (0.2–0.8) 2,288 10 0.4 (0.2–0.7) -20.0
T. trichiura 2,348 75 3.2 (2.5–3.9) 2,288 39 1.7 (1.2–2.2) -46.9
Arm C
S. mansoni 2,253 612 27.2 (25.3–29.0) NA
Hookworm 2,253 55 2.4 (1.8–3.1) NA
A. lumbricoides 2,253 31 1.4 (0.9–1.9) NA
T. trichiura 2,253 64 2.8 (2.2–3.5) NA
Overall
S. mansoni 7,011 1,547 22.1 (19.5–24.4) 4,667 598 12.8 (11.9–13.8) -42.1
Hookworm 7,011 95 1.4 (1.1–1.6) 4,667 4 0.1 (0.0–0.2) -92.9
A. lumbricoides 7,011 66 0.9 (0.7–1.2) 4,667 21 0.4 (0.3–0.6) -55.6
T. trichiura 7,011 221 3.2 (2.7–3.6) 4,667 81 1.7 (1.4–2.1) -46.9
Prevalence of S. mansoni and soil-transmitted helminth infections among 9- to 12-year-old schoolchildren in the schools belonging to treatment arms A
and B, respectively, at the baseline survey, which was conducted from December 2011 to February 2012, and the first follow-up survey, which was carried
out one-year post-treatment in May 2013, in western Côte d’Ivoire.
Arm A: schools receive praziquantel treatment annually for four years, Arm B: schools receive praziquantel treatment in the first two years of the study,
followed by two years of “drug holiday”; Arm C: schools receive praziquantel treatment in the first and third year of the study and have “drug holidays” in
the second and fourth year.
CI: confidence interval; NA: not assessed.
doi:10.1371/journal.pntd.0004329.t001
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(64.0%) out of the 25 surveyed schools (S1 Table). However, a statistically significant decrease
in AM EPG from 33.0 EPG (95% CI: 13.9–52.0 EPG) to 5.5 EPG (95% CI: 3.8–7.2 EPG) was
observed in only one school; Tobly Bangolo. Increases in S.mansoni AM EPG were observed
in nine schools. However, the increase lacked statistical significance in all schools. In treatment
arm A, the proportion of children with moderate (100–399 EPG) and heavy infections (400
EPG) increased from 9.5% to 13.5% and from 4.6% to 7.2%, respectively.
In arm B, a decrease of the S.mansoni infection intensity was observed in 13 (52.0%) out of
the 25 schools (S1 Table). With the exception of one school, this decrease was not statistically
significant. The AM EPG decreased significantly in Mangouin school from 178.0 EPG (95%
CI: 77.7–278.3 EPG) to 30.4 EPG (95% CI: 4.2–56.6 EPG). In the remaining 12 schools, the
AM EPG increased, but these increases lacked statistical significance. The proportion of chil-
dren with moderate and heavy infection intensities increased from 12.9% to 18.7%, while the
proportion of heavy infections decreased slightly from 6.0% to 5.7%.
Fig 2. Dynamics of the S.mansoni prevalence in schools of treatment arms A and B. The graphs show the change of the S.mansoni prevalence from
the baseline survey, which was conducted from December 2011 to February 2012, to the first follow-up survey, which was carried out one-year post-
treatment in May 2013, in 9- to 12-year-old schoolchildren from 25 schools per treatment arm in western Côte d’Ivoire. Arm A: schools receive praziquantel
treatment annually for four years, Arm B: schools receive praziquantel treatment the first two years of the study, followed by two years of “drug holiday”. Red
star: S.mansoni prevalence increased significantly.
doi:10.1371/journal.pntd.0004329.g002
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Fig 3B shows the spatial distribution of S.mansoni AM EPG reduction after the intervention
in the study area. The AM EPG decreased by at least 25% in 25 schools (50.0%). In eight
schools (16.0%), the change varied from -25% to +25%. The AM EPG increased by 25% and
more in 17 schools (34.0%). An increase of S.mansoni infection intensity by 25% and more
was only focally observed; in Tonkpi region and central Guemon region.
Fig 3. S.mansoni prevalence and infection intensity (AM EPG) at the baseline and follow-up survey. The maps show the spatial distribution of the
changes in the S.mansoni prevalence and in the infection intensity expressed as arithmetic mean eggs per gram of feces (AM EPG) between the baseline
survey (A), which was conducted from December 2011 to February 2012, and the first follow-up survey (B), which was carried out one-year post-treatment in
May 2013, in western Côte d’Ivoire. Arm A: schools receive praziquantel treatment annually for four years, Arm B: schools receive praziquantel treatment the
first two years of the study, followed by two years of “drug holiday”.
doi:10.1371/journal.pntd.0004329.g003
Table 2. S.mansoni infection intensity in the schools belonging to treatment arms A, B, and C.
Arm Baseline One-year post-MDA Change
No. No. Arithmetic mean
EPG
Light Moderate Heavy No. No. Arithmetic mean
EPG
Light Moderate Heavy
examined positive (95% CI) (%) (%) (%) examined positive (95% CI) (%) (%) (%) (%)
Arm A 2,410 453 93.5 (62.6–124.4) 85.9 9.5 4.6 2,379 266 123.7 (70.7–176.7) 79.3 13.5 7.2 -32.2
Arm B 2,348 482 96.2 (74.5–117.9) 81.1 12.9 6.0 2,288 332 97.8 (75.5–120.0) 75.6 18.7 5.7 -1.7
Arm C 2,253 612 88.1 (71.5–104.7) 77.1 18.8 4.1 NA NA NA NA NA NA
Overall 7,011 1,547 92.2 (79.2–105.3) 80.9 14.2 4.9 4,667 598 109.3 (82.7–135.9) 77.3 16.4 6.3 -18.5
S. mansoni arithmetic mean intensity of infection among 9- to 12-year-old schoolchildren in the schools belonging to treatment arms A, B, and C,
respectively, as determined at the baseline survey, which was conducted from December 2011 to February 2012, and the first follow-up survey, which
was carried out one-year post-treatment in May 2013, in western Côte d’Ivoire.
Arm A: schools receive praziquantel treatment annually for four years, Arm B: schools receive praziquantel treatment in the first two years of the study,
followed by two years of drug holiday; Arm C: schools receive praziquantel treatment in the first and third year of the study and have “drug holidays” in the
second and fourth year.
NA: not assessed; CI: confidence interval; EPG: eggs per gram of feces.
doi:10.1371/journal.pntd.0004329.t002
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Coverage of SBT
During the SBT carried out in June 2012, the estimated number of the school-aged population
in the study area was 31,832 children. Among them, 26,804 swallowed praziquantel tablets at
the SBT, resulting in an overall DOT coverage of 84.2%. Stratified by treatment arm, we found
a DOT coverage of 79.2% (range: 31.9–97.9%) for arm A, 84.8% (range: 61.5–98.5%) for arm B,
and 88.4% (range: 75.1–98.9%) for arm C.
The individual DOT coverage rates achieved in the 75 villages are shown in S2 Table. A cov-
erage of 75% and above was achieved in 57 schools (76.0%), while a coverage of less than 75%
Fig 4. Dynamics of the S.mansoni infection intensity in schools of treatment arms A and B. The graphs show the change of the S.mansoni infection
intensity expressed as change in arithmetic mean eggs per gram of feces (AM EPG) from the baseline survey, which was conducted from December 2011 to
February 2012, to the first follow-up survey, which was carried out one-year post-treatment in May 2013, in 9- to 12-year-old schoolchildren from 25 schools
per treatment arm in western Côte d’Ivoire. Arm A: schools receive praziquantel treatment annually for four years, Arm B: schools receive praziquantel
treatment the first two years of the study, followed by two years of “drug holiday”. Red star: S.mansoni infection intensity decreased significantly.
doi:10.1371/journal.pntd.0004329.g004
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was reported in the remaining 18 schools. Yaoudé (in arm A) reported a coverage below 50%.
The DOT coverage was not significantly correlated with changing levels of S.mansoni preva-
lence (Spearman ρ = -0.11; p = 0.43), while it was significantly correlated with AM EPG (Spear-
man ρ = 0.32; p = 0.02) (Fig 5).
Discussion
Preventive chemotherapy with praziquantel is the backbone of the global strategy against schis-
tosomiasis and other helminthiases [12,29]. Our findings show that one year after an initial
treatment with praziquantel in 50 schools of western Côte d’Ivoire that met inclusion criteria
of a SCORE harmonization protocol (prevalence ranging between 10% and 24%) [15], the
overall S.mansoni prevalence was reduced from 19.7% to 12.8%, while there was no significant
change in the overall AM EPG. The overall DOT coverage in the study area was 84.2%; hence,
above the 75% coverage recommended by WHO [16]. At school level, the picture on the
impact of the SBT was less clear cut. Decreases in prevalence and infection intensity were
observed in some schools and increases in others. Among the six schools that showed higher
prevalences of S.mansoni at the 1-year follow-up compared with baseline, in only one school,
the treatment coverage was<75%. The changes in the AM EPG level were significantly corre-
lated with the coverage rate.
The overall reduction of the S.mansoni prevalence in the first year of this SCORE project
(35.0%) is in line with studies assessing the S.mansoni prevalence 12 months post-MDA in
central Sudan and Uganda, where reductions of S.mansoni prevalence of 36.7% and 39.5%
were observed, respectively [30,31]. The treatment coverage in these two studies was reported
to be 100% and 79.2%, respectively [31,32]. In the Sudan study, treatment of children with pra-
ziquantel was conducted by trained nurses and medical officers, while in Uganda, the treatment
was carried out by trained teachers and community drug distributors [31,32]. A survey con-
ducted 6 months after praziquantel treatment in Sierra Leone where the overall treatment cov-
erage was 94.0% found a reduction of the S.mansoni prevalence of 44.6% [33]. Another study
carried out in Sierra Leone reported an even higher reduction in the S.mansoni prevalence of
Fig 5. Correlation between coverage rate and the changes in the S.mansoni infection intensity.
Scatter plot illustrating the correlation between the coverage rates achieved in a directly observed school-
based treatment round implemented in 50 schools in western Côte d’Ivoire in June 2012, and the % changes
in the S.mansoni arithmetic mean infection intensity observed between the baseline survey, which was
conducted from December 2011 to February 2012, and the first follow-up survey, which was carried out one-
year post-treatment in May 2013, in 9- to 12-year-old schoolchildren.
doi:10.1371/journal.pntd.0004329.g005
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67.2%, as determined three years after three rounds of praziquantel administration [34]. In
contrast, studies conducted in Zambia and Kenya showed that 2 years after the withdrawal of
praziquantel treatment led to an increase of S.mansoni prevalence [35,36]. It is important to
note that these studies showed that the impact of MDA on the S.mansoni prevalence varied
depending on the infection status in a given area, and the frequency and number of treatment
rounds. Repeated treatments over short time periods can lead to a high reduction in S.mansoni
prevalence compared to longer treatment intervals. Similar baseline S.mansoni prevalences
were observed in two preceding studies in Sierra Leone and Uganda (49% and 42%, respec-
tively), but the decrease in S.mansoni prevalence was lower in Uganda, where the intensity of
infection, and thus the level of transmission, was higher. A plausible explanation of this obser-
vation arises from rapid re-infection, which is related to the force of infection, and which is
likely higher where S.mansoni transmission is intense. Indeed, the level of schistosomiasis
transmission, which is governed by various factors, such as local environmental determinants,
climate, water contact patterns, intermediate host snail distribution, and ecology, may affect
the impact of MDA [37–40]. When interpreting these results, one has to bear in mind, how-
ever, that the prevalence of S.mansoni was determined by an insensitive diagnostic approach;
single stool samples subjected by single (Uganda) or duplicate Kato-Katz thick smears (Sierra
Leone). Hence, the diagnostic approach was less rigorous than in the current study in Côte
d’Ivoire, where only those children who had at least quadruplicate Kato-Katz thick smears
examined before and after treatment were included in the final analysis.
In our study, in the schools Biélé and Ziondrou, the S.mansoni prevalence had significantly
increased one year after SBT with levels in excess of 60%. Since the DOT coverage in both
schools was high (75.2% in Biélé and 91.9% in Ziondrou), we assume that there are major
transmission hotspots in the area, where children become rapidly re-infected. Re-emergence of
S.mansoni and S. haematobium after treatment in high-endemicity areas has previously been
reported from other studies in Côte d’Ivoire and Niger [41,42]. One explanation might be
migration of people, including those infected with S.mansoni or S. haematobium, into treated
villages. A considerable population movement has, for example, been observed in Côte d’Ivoire
due to socio-political unrest in 2011 [43], hence at the start of our study. A lack of access to
safe water, sanitation, and hygiene (WASH) might also be the reason for rapid reinfection.
Noteworthy, when interviewing the local village leaders, they reported that people in the area
frequently use well water for washing and bathing, while ponds and rivers serve as the main
natural water contact sites. While some houses have latrines, many people still practice open
defecation. Another explanation of the increase in S.mansoni prevalence might be the target
population of the treatment strategy. The present study focused on school-aged children. Pre-
school-aged children and adults also harbor Schistosoma worms, and hence, they act as reser-
voir of transmission source of re-infections [36]. Yet, there are other local conditions that
might foster S.mansoni transmission in Biélé and Ziondrou that warrant further investigation.
For example, one might want to assess the frequency and duration of water contact in children
and associated re-infection patterns, and the transmission force caused by intermediate host
snails populating waterbodies located in close proximity to the surveyed schools. It will be
important to assess in future surveys whether individuals had indeed received praziquantel in
the past treatment round, or whether they were immigrating from other areas after the last sur-
vey, or had traveled to highly endemic areas over the past year. Ideally, the reinfection pattern
would be determined by following a cohort of children, including immunological markers of
the individuals that might favor or delay reinfection, and molecular markers of the infecting
parasites.
An increase of S.mansoni infection within the frame of ongoing treatment programs has
also been observed elsewhere. In Senegal, for example, an elevated S.mansoni prevalence was
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found 10 months after praziquantel administration [44]. More recently, in Ségou district in
Mali, the national control program had revealed an increase of the S.mansoni prevalence after
four rounds of MDA in 7- to 14-year-old children [45]. It has been assumed that these
increases of S.mansoni infections after praziquantel treatment might be explained by partial
resistance to praziquantel, the acquisition of new infection, and high force of transmission
[46–48].
Taken together, our data show that SBT resulted in marked decreases of S.mansoni preva-
lence, but the intensity of infection among infected children did not change significantly.
Hence, with a single treatment round, the force of transmission in terms of egg excretion in the
school-aged population has not been changed in most of our study schools. Monitoring the
impact of multiple treatment rounds and “drug holidays” over the next years will provide
stronger evidence of what multiple SBT rounds can achieve [13,15].
Clearly, sustainable control and eventual elimination of schistosomiasis requires multiple
intervention packages, such as preventive chemotherapy (perhaps extended to all age groups),
intensified case management, control of intermediate host snails, provision of WASH, and set-
ting-specific information, education, and communication (IEC) [49–51]. In Côte d’Ivoire, the
control of schistosomiasis at a national scale is still at an early stage. Indeed, the PNL-SGF was
only launched shortly before this SCORE project. For the success and sustainability of schisto-
somiasis control in Côte d’Ivoire–and elsewhere in sub-Saharan Africa–it will be important
that, in addition to preventive chemotherapy, other control measures are considered and
implemented [6,7,49,52].
The present study showed that one year after SBT with praziquantel, the overall prevalence
of S.mansoni infection had decreased significantly. However, in certain hotspot schools, the S.
mansoni prevalence had increased unexpectedly. The infection intensity among S.mansoni-
infected children was similar at the 1-year follow-up. These results demonstrated that the
dynamic of schistosomiasis in the study areas is heterogeneous and that a single round of treat-
ment is insufficient to have a lasting effect. It will be important to monitor the dynamic of
schistosomiasis over the course of this SCORE study, in order to deepen our understanding of
the dynamics of schistosomiasis transmission in a moderately endemic setting.
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